ARQT
Arcutis Biotherapeutics Inc (ARQT)
Healthcare • NASDAQ • $21.17+2.47%
- Symbol
- ARQT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $21.17
- Daily Change
- +2.47%
- Market Cap
- $2.65B
- Trailing P/E
- N/A
- Forward P/E
- 18.32
- 52W High
- $31.77
- 52W Low
- $12.72
- Analyst Target
- $34.63
- Dividend Yield
- N/A
- Beta
- 1.59
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Company websiteResearch ARQT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.